We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




World’s First GFAP Lateral Flow Test Demonstrates Potential for Rapid TBI Diagnosis

By LabMedica International staff writers
Posted on 19 Aug 2025

Traumatic Brain Injury (TBI) affects millions of people globally each year, ranging from mild concussions to severe neurological trauma. More...

Accurate and timely diagnosis is critical, as delays can lead to poor outcomes and long-term disability. Traditionally, Glial Fibrillary Acidic Protein (GFAP), a biomarker of brain injury, has only been measurable using complex laboratory assays or bulky point-of-care systems that are not ideal for emergency settings. Now, a landmark study has demonstrated the development and successful clinical application of the world’s first lateral flow test for measuring GFAP, paving the way for rapid and accurate TBI diagnosis.

The novel GFAP lateral flow device developed by Upfront Diagnostics (Cambridge, UK), in collaboration with global partners, measures GFAP, a protein released into the bloodstream following brain injury that has emerged as a key biomarker for TBI. This handheld diagnostic tool is designed for emergency use and enables healthcare professionals to detect brain injury biomarkers at the point of care.

By translating the principles of traditional lateral flow tests into a format optimized for neurological biomarkers, the device allows GFAP levels to be measured in minutes. This innovation provides the same speed and simplicity as a rapid diagnostic test but with the sensitivity required to aid in life-saving decisions. The landmark study, published in Cellular and Molecular Neurobiology, has reported the successful clinical application of the device. Researchers confirmed its unprecedented speed and accuracy in diagnosing TBI at the bedside. Validation across diverse clinical settings demonstrated that the test could reliably identify patients with brain injury, making it the first proven rapid lateral flow test for GFAP measurement.

The potential applications of this device extend well beyond research. Clinicians will be able to reduce unnecessary CT scans, streamline triage protocols, and accelerate care delivery in emergency departments. By providing reliable results quickly, the test could shorten the time to intervention and significantly improve patient outcomes. Upfront Diagnostics plans to advance this technology further, ensuring that it reaches frontline clinicians globally.

“We are incredibly proud to introduce the first rapid lateral flow GFAP test in history—this is a true game-changer for TBI diagnosis. By enabling fast and reliable GFAP measurement at the point of care, we can empower healthcare professionals to make more informed decisions—potentially saving lives and reducing the long-term consequences of brain injury,” said Dr. Joshua Bernstock, Chief Medical Officer at Upfront Diagnostics.

Related Links:
Upfront Diagnostics


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Collection and Transport System
PurSafe Plus®
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: Automated cell imaging discriminates CD8+ T cells according to natalizumab treatment outcome in MS patients (B Chaves et al., Nat Commun 16, 5533 (2025). DOI: 10.1038/s41467-025-60224-3)

Novel Tool Predicts Most Effective Multiple Sclerosis Medication for Patients

Multiple sclerosis (MS) is a chronic autoimmune and degenerative neurological disease that affects the central nervous system, leading to motor, cognitive, and mental impairments. Symptoms can include... Read more

Technology

view channel
Image: The SWITCH hybrid pipette is designed to simplify and accelerate pipetting tasks (Photo courtesy of INTEGRA)

Hybrid Pipette Combines Manual Control with Fast Electronic Aliquoting

Manual pipettes offer the control needed for delicate tasks such as mixing or supernatant removal, but typically fall short in repetitive workflows like aliquoting. Electronic pipettes solve this problem... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.